Favipiravir (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Favipiravir" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

19doi.org

2^nd place

4^th place

17nih.gov

4^th place

13^th place

12web.archive.org

1^st place

2reuters.com

49^th place

96^th place

1nhk.or.jp

145^th place

1,512^th place

1xinhuanet.com

309^th place

427^th place

1harvard.edu

18^th place

44^th place

1bloomberg.com

99^th place

159^th place

1diamond.jp

2,938^th place

low place

1clinicaltrials.gov

5,225^th place

low place

1allafrica.com

1,467^th place

3,401^st place

1nytimes.com

7^th place

35^th place

1sciencemag.org

857^th place

574^th place

1theguardian.com

12^th place

49^th place

allafrica.com

"Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica – All the Time. Diarsipkan dari versi asli tanggal 2016-03-23. Diakses tanggal 20 Maret 2020.

bloomberg.com

Koons, Cynthia (7 Agustus 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com. Diarsipkan dari versi asli tanggal 2015-01-07. Diakses tanggal 2020-03-20.

clinicaltrials.gov

"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". FDA. Diarsipkan dari versi asli tanggal 2022-12-11. Diakses tanggal 20 Maret 2020.

diamond.jp

条件付き承認で普及に足かせ富山化学インフル薬の"無念". Diarsipkan dari versi asli tanggal 2020-04-09. Diakses tanggal 20 Maret 2020.

doi.org

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (Juni 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838 . PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLoS Neglected Tropical Diseases. 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105 . PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322 . PMID 27547128.
Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667 . PMID 26655300.
Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (Januari 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report (dalam bahasa Inggris). 67 (5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827 . PMID 30605446.
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847 . PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology. 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194 . PMID 23325689.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (Maret 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLoS Medicine. 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946 . PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (Oktober 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635 . PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (Oktober 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". Molecular Pharmacology. 84 (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (Agustus 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843 . PMID 29891600.
Hayden, Frederick. "Influenza virus polymerase inhibitors in clinical development". Current Opinion in Infectious Diseases. doi:10.1097/QCO.0000000000000532. Diarsipkan dari versi asli tanggal 2023-04-29.
Gatherer D (Agustus 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (Mei 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". Antiviral Research. 104: 153–55. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.
Cohen, Jon (26 Februari 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. Diarsipkan dari versi asli tanggal 2020-02-19. Diakses tanggal 20 Maret 2020.
Dong, L; Hu, S; Gao, J (2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". Drug discoveries & therapeutics. 14 (1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.

dx.doi.org

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 Feb DOI:10.1038/d41573-020-00016-0

harvard.edu

adsabs.harvard.edu

Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847 . PMID 23874596.

nhk.or.jp

www3.nhk.or.jp

"NHK World News 'China: Avigan effective in tackling coronavirus'". Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.

nih.gov

ncbi.nlm.nih.gov

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (Juni 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838 . PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLoS Neglected Tropical Diseases. 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105 . PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322 . PMID 27547128.
Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667 . PMID 26655300.
Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (Januari 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report (dalam bahasa Inggris). 67 (5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827 . PMID 30605446.
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847 . PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology. 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194 . PMID 23325689.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, et al. (Maret 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLoS Medicine. 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946 . PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (Oktober 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635 . PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (Oktober 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". Molecular Pharmacology. 84 (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. (Agustus 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843 . PMID 29891600.
Hayden, Frederick. "Influenza virus polymerase inhibitors in clinical development". Current Opinion in Infectious Diseases. doi:10.1097/QCO.0000000000000532. Diarsipkan dari versi asli tanggal 2023-04-29.
Gatherer D (Agustus 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (Mei 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". Antiviral Research. 104: 153–55. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.
Dong, L; Hu, S; Gao, J (2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". Drug discoveries & therapeutics. 14 (1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.

nytimes.com

Fink, Sheri (4 Februari 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times. Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.

reuters.com

BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus Diarsipkan 2020-03-13 di Wayback Machine.. Reuters Healthcare, 20 Maret 2020.
"First French Ebola patient leaves hospital". Reuters. 4 Oktober 2016. Diarsipkan dari versi asli tanggal 2020-02-19. Diakses tanggal 2020-03-20.

sciencemag.org

Cohen, Jon (26 Februari 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. Diarsipkan dari versi asli tanggal 2020-02-19. Diakses tanggal 20 Maret 2020.

theguardian.com

"Japanese flu drug 'clearly effective' in treating coronavirus, says China". The Guardian. 2020-03-18. Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 20 Maret 2020.

web.archive.org

BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus Diarsipkan 2020-03-13 di Wayback Machine.. Reuters Healthcare, 20 Maret 2020.
"NHK World News 'China: Avigan effective in tackling coronavirus'". Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.
"Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 Maret 2020". Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.
Koons, Cynthia (7 Agustus 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com. Diarsipkan dari versi asli tanggal 2015-01-07. Diakses tanggal 2020-03-20.
Hayden, Frederick. "Influenza virus polymerase inhibitors in clinical development". Current Opinion in Infectious Diseases. doi:10.1097/QCO.0000000000000532. Diarsipkan dari versi asli tanggal 2023-04-29.
条件付き承認で普及に足かせ富山化学インフル薬の"無念". Diarsipkan dari versi asli tanggal 2020-04-09. Diakses tanggal 20 Maret 2020.
"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". FDA. Diarsipkan dari versi asli tanggal 2022-12-11. Diakses tanggal 20 Maret 2020.
"First French Ebola patient leaves hospital". Reuters. 4 Oktober 2016. Diarsipkan dari versi asli tanggal 2020-02-19. Diakses tanggal 2020-03-20.
"Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica – All the Time. Diarsipkan dari versi asli tanggal 2016-03-23. Diakses tanggal 20 Maret 2020.
Fink, Sheri (4 Februari 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times. Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.
Cohen, Jon (26 Februari 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. Diarsipkan dari versi asli tanggal 2020-02-19. Diakses tanggal 20 Maret 2020.
"Japanese flu drug 'clearly effective' in treating coronavirus, says China". The Guardian. 2020-03-18. Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 20 Maret 2020.

xinhuanet.com

"Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 Maret 2020". Diarsipkan dari versi asli tanggal 2020-03-18. Diakses tanggal 2020-03-20.